Illumina closes $8bn acquisition of cancer detection tests provider GRAIL
Illumina will operate GRAIL as a separate entity, as the transaction is currently under European Commission (EC)’s regulatory…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Aug 21
Illumina will operate GRAIL as a separate entity, as the transaction is currently under European Commission (EC)’s regulatory…
18 Aug 21
The SDNA-1000 saliva collection device serves as a noninvasive way to collect, neutralise, stabilise, and transport testing samples
17 Aug 21
The new method, which avoids extraction of the virus’ genetic RNA material, is said to simplify purification and…
17 Aug 21
The new TaqPath assays have been developed with increased target redundancy to recoup for current mutations, as well…
17 Aug 21
Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied…
16 Aug 21
The new Covid-19 test is designed to detect and differentiate all the new mutating Covid-19 variants
Robust, dual-target test now available for sale in Australia
11 Aug 21
The companies will also focus on the development of Fluorescence Immunoassay and Electrophoresis-based diagnostic solutions
11 Aug 21
Acquisition expands anatomic pathology equipment product portfolio to better serve global customer base
10 Aug 21
The acquisition of CSI will allow Fulgent to significantly expand its capabilities in molecular diagnostics and oncologic testing